Riskpilot← Back to searchSign inGet full accessMD Biomedical AB
ABActiveOrg 5568370273Verkstadsgatan 8Research and experimental development on natural sciences and engineering · NACE 7210Est. 20110 employees
Revenue 2024
SEK 0
EBITDA margin
—
+33% vs 2023
Equity ratio
10.7%
Financial strength
Net profit 2024
SEK -2K
+33% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -2K | +33% |
| Net profit | SEK -2K | +33% |
| Total assets | SEK 281K | -1% |
| Equity | SEK 30K | -3% |
| Employees | 0 | — |
Legal name
MD Biomedical AB
Org number
5568370273
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4 januari 2011
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva medicinsk teknik, produktutveckling av microdialys katetrar, konsult inom mikrodialystekniken, försäljning av mikrodialyskatetrar, tillbehör till mikro- dialyskatetrar och analysutrustning för analys av prover tagna med mikrodialystekniken, samt därmed förenlig verksamhet.
Address
Verkstadsgatan 8
Email
info@senzime.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −202 | −1 | −3 | −3 | −2 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −202 | −1 | −3 | −3 | −2 |
| Net financials | — | — | — | — | — |
| Profit before tax | −202 | −1 | −3 | −3 | −2 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −202 | −1 | −3 | −3 | −2 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 289 | 288 | 285 | 283 | 281 |
| Equity | 38 | 37 | 34 | 31 | 30 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 251 | 251 | 251 | 251 | 251 |
| Total debt | 251 | 251 | 251 | 251 | 251 |
EBITDA margin
-200000.0%
This company
15.8%
Market median
-1265923% vs market
20202024
Equity ratio
10.7%
This company
38.2%
Market median
-72% vs market
20202024
Return on equity
-6.7%
This company
18.4%
Market median
-136% vs market
20202024
Net profit margin
-200000.0%
This company
8.1%
Market median
-2469236% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
8.37×
This company
0.62×
Market median
-1250% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Chairman | 2022 | |
| Deputy Board Member | 2020 | |
| Former (1) | ||
| Chairman | 2022 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Senzime AB (publ.)
MD Biomedical AB Board members of MD Biomedical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Slavoljub Grujicic | Board of Directors | 0 companies |
| Philip Axel Wilhelm Siberg | Chairman | 0 companies |
| Pia Monica Henriksson Renaudin | Chairman | 0 companies |
| Anders Bertil Jakobson | Deputy Board Member | 0 companies |